Clinical Trial Update: Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) [Phase 3]

View source ↗

Summary

Update on the Phase 3 CRYSTAL trial evaluating cetuximab with irinotecan as first-line therapy for metastatic colorectal cancer; the study is completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2011-02-23